A mouse-adapted strain of human enterovirus 71 (HEV71) was selected by serial passage of a HEV71 clinical isolate (HEV71-26M) in Chinese hamster ovary (CHO) cells (CHO-26M) and in newborn BALB/c mice (MP-26M). Despite improved growth in CHO cells, CHO-26M did not show increased virulence in newborn BALB/c mice compared with HEV71-26M. By contrast, infection of newborn mice with MP-26M resulted in severe disease of high mortality. Skeletal muscle was the primary site of replication in mice for both viruses. However, MP-26M infection induced severe necrotizing myositis, whereas CHO-26M infection caused only mild inflammation. MP-26M was also isolated from whole blood, heart, liver, spleen and brain of infected mice. CHO-26M harboured a single mutation within the open reading frame (ORF), resulting in an amino acid substitution of K 149 AI in the VP2 capsid protein; two further ORF mutations that resulted in amino acid substitutions were identified in MP-26M, located within the VP1 capsid protein (G 145 AE) and the 2C protein (K 216 AR). Infectious cDNA clone-derived mutant virus populations containing the mutations identified in CHO-26M and MP-26M were generated in order to study the molecular basis of CHO cell and mouse adaptation. The VP2 (K 149 AI) change was responsible only for improved growth in CHO cells and did not lead to increased virulence in mice. Of the two amino acid substitutions identified in MP-26M, the VP1 (G 145 AE) mutation alone was sufficient to increase virulence in mice to the level observed in MP-26M-infected mice.
INTRODUCTION
Human enterovirus 71 (HEV71) belongs to the species Human enterovirus A of the genus Enterovirus within the family Picornaviridae (Stanway et al., 2005) . It is composed of a single-stranded, positive-sense RNA of approximately 7500 nt surrounded by an icosahedral capsid assembled from 60 copies of each of the four structural proteins, VP1, VP2, VP3 and VP4. HEV71 was first isolated from an infant with encephalitis in California in 1969 (Schmidt et al., 1974) and has since been associated with large outbreaks of hand, foot and mouth disease in young children, most recently in the Asia-Pacific region (Chumakov et al., 1979; Lum et al., 1998; McMinn et al., 2001a) . Although hand, foot and mouth disease is considered a mild febrile exanthem of childhood, HEV71 infection is associated with a high prevalence of severe neurological disease, including aseptic meningitis, brainstem and/or cerebellar encephalitis and acute flaccid paralysis (reviewed by McMinn, 2002) . With the almost successful eradication of poliomyelitis, HEV71 is now the leading cause of acute neurological infection in children of several Asian countries. Despite this, little is known about the pathogenesis of severe disease caused by HEV71.
Similar to the related poliovirus, HEV71 has a limited host range, with humans the only known natural host. Although Old World monkeys such as cynomolgus, rhesus and African green monkeys can be infected experimentally with HEV71 (Arita et al., 2005; Chumakov et al., 1979; Hashimoto & Hagiwara, 1982; Hashimoto et al., 1978) , other animal species, including rodents, are resistant to infection. Unfortunately, the high cost of monkeys and their maintenance precludes their widespread use for studies of viral pathogenesis. Thus, a small animal model would provide a more cost-effective and practical tool for studies of HEV71 pathogenesis and for vaccine development. intramuscular (i.m.), intraperitoneal (i.p.) or intracerebral (i.c.) inoculation developed acute flaccid paralysis mimicking HEV71 infection in humans and monkeys (Chen et al., 2004; Wang et al., 2004) . Mouse-adapted HEV71 was more virulent in mice, exhibited a larger plaque size and grew more rapidly in cell culture than parental virus. Potential virulence determinants of this mouse-adapted strain were identified in the 59-untranslated region (four nucleotide changes), the capsid protein VP2 (three nucleotide and one amino acid change) and the nonstructural protein 2C (eight nucleotide and four amino acid changes) . However, the role of these mutations in the virulence phenotype of the mouseadapted strain was not determined.
In order to establish a mouse model for studies of HEV71 pathogenesis and for vaccine efficacy and immunogenicity testing, we selected a mouse-adapted variant of HEV71 by serial passage of a recent clinical isolate. We also report on the molecular mechanism of mouse adaptation and virulence of HEV71 in this model.
METHODS

Cells and viruses. African green monkey kidney (Vero) cells (ATCC CCL-81), human rhabdomyosarcoma (RD) cells (ATCC CCL-136), simian virus 40-transformed African green monkey kidney (COS-7)
cells (ATCC CRL-1651) and Chinese hamster ovary (CHO) cells (ATCC CCL-61) were maintained in Dulbecco's modified Eagle's medium (DMEM) (MultiCel; Trace Biosciences) supplemented with 5 % bovine growth serum (BGS) (MultiSer; Trace Biosciences) and 2 mM L-glutamine. HEV71 strain 26M/AUS/4/99 (HEV71-26M) was isolated in Western Australia in 1999 (McMinn et al., 2001a) . HEV71-26M was plaque purified and propagated by six passages in RD cells. To generate mouse-adapted HEV71, parental HEV71-26M was first adapted to growth in CHO cells by six passages at an m.o.i. of 1. CHO-adapted HEV71-26M (CHO-26M) was then passaged six times by i.c. inoculation of 1-day-old BALB/c mice with 10 3 TCID 50 virus obtained from clarified brain homogenates. Mouse-adapted virus derived from the sixth mouse brain passage was passaged a further two times in Vero cells and designated MP-26M.
RNA extraction, cDNA synthesis and nucleotide sequence analysis. RNA was extracted from HEV71-infected cell culture supernatants using a QIAamp viral RNA mini kit (Qiagen). Firststrand cDNA synthesis was undertaken using SuperScript II reverse transcriptase (Invitrogen); viral cDNA was amplified using PCR SuperMix (Invitrogen) with gene-specific primers and gel purified using a MinElute gel extraction kit (Qiagen). Nucleotide sequences of the whole genome of HEV71-26M, CHO-26M and MP-26M, infectious cDNA clone-derived virus (CDV) genomic fragments and plasmid DNA were determined by automated DNA sequencing using Big Dye Terminator sequencing technology. Sequencing was performed at the Australian Genome Research Facility, University of Queensland, Australia. Sequence analysis was performed using Chromas version 2.3 (Technelysium Pty) and Clone Manager 5/Align Plus 4 software (SciEd Central).
Construction of full-length infectious cDNA clones of HEV71-26M and variants
Full-length infectious cDNA clones of HEV71-26M, CHO-26M and MP-26M were constructed using RT-PCR, restriction enzyme digestion and cloning, as described below. All viral cDNA fragments used for cloning were amplified by PCR using Platinum Taq DNA Polymerase High Fidelity (Invitrogen). Competent Escherichia coli strain XL10-Gold (Stratagene) was used for cloning and amplification of all plasmid constructs. Clones were screened by restriction enzyme digestion and sequencing. A schematic diagram of the infectious cDNA clones prepared in this study is presented in Fig. 1. pHEV71-26M The full-length cDNA clone of HEV71-26M was constructed in two subgenomic clones, using plasmid pMC18 (Gualano et al., 1998) . Plasmid pMC/59-26M contained nt 1-3114 of HEV71-26M, preceded by a SalI restriction site to facilitate cloning, a T7 RNA polymerase promoter and two additional 59 G residues to improve transcription efficiency (Boyer & Haenni, 1994 Infectious cDNA clones were transfected into COS-7 cells using Lipofectamine 2000 (Invitrogen). Briefly, COS-7 cells were seeded into 12-well tissue-culture trays (CellStar) at a seeding density of 3610 5 cells per well. After incubation for 18-24 h, cells were washed with PBS (pH 7.4) and replaced with serum-free medium (Optimem; Invitrogen) prior to transfection. The lipid-nucleic acid complex containing 1.6 mg of each full-length cDNA construct, 1.6 mg pCMVT7Pol expressing the T7 RNA polymerase and 4 ml Lipofectamine 2000 was added to the cells and incubated for 4 h. The transfection medium was then removed and replaced with DMEM supplemented with 2 mM L-glutamine and 2 % BGS and the cells incubated for a further 72 h. Transfected cells were subjected to three cycles of freezethawing and the supernatants clarified by centrifugation at 1000 g for 15 min. CDV stocks were passaged once on RD cells and stored at 280 uC until required. CDV stocks are designated as such by the prefix CDV to distinguish them from their respective parental virus. Reed & Muench (1938) . Vero cell monolayers (10 4 cells per well) in 96-well tissue-culture trays (CellStar) were inoculated with 100 ml 10-fold serial dilutions of each virus stock and incubated for 5 days prior to observation of the presence of cytopathic effect.
RD and CHO cell monolayers grown overnight in 48-well tissueculture trays (5610 4 cells per well) were infected at an m.o.i. of 5 for 1 h at 37 uC. Inoculated cells were then washed three times with PBS and overlaid with 200 ml maintenance medium (DMEM supplemented with 2 mM L-glutamine and 2 % BGS) per well. Cells and supernatants were collected every 4 h for 24 h, with the first time point (time 0) collected immediately after the addition of the maintenance medium. Samples at each time point were frozen and thawed three times and clarified by centrifugation at 8000 g for 10 min prior to the determination of the virus titre by the TCID 50 assay.
Mouse virulence assays. Specific-pathogen-free pregnant BALB/c mice were obtained from the Animal Resources Centre, Perth, Australia. All experiments were performed on the ensuing litters of newborn mice. Mice were housed in filter-topped cages on a deep litter of sawdust and were provided with food and water ad libitum. All mouse studies were approved by the institutional Animal Experimentation Ethics Committee.
In order to minimize distress, 50 % humane end points (HD 50 ) were used instead of 50 % lethal end points; HD 50 values are calculated from the time of onset of lethal infection (see below) instead of waiting until death ensues. Humane end-point assays have been found to be almost identical to lethal end-point virulence assays (Wright & Phillpotts, 1998) .
Groups of four to ten 1-or 7-day-old BALB/c mice were infected with serial 10-fold dilutions of virus by i.c., i.p. or i.m. inoculation and HD 50 values were calculated by the method of Reed & Muench (1938) . Mean survival time was calculated in groups of ten 7-day-old BALB/c mice after i.m. inoculation of 10 4 TCID 50 virus. Infected mice were observed twice daily for clinical signs of illness up to 21 days post-infection (p.i.). Mice that developed clinical signs of HEV71 infection, including dehydration, lack of feeding, a hunched back, paresis and fore-and/or hindlimb paralysis, were sacrificed by an overdose of pentobarbitone sodium (100 mg kg 21 by i.p. injection).
Tissue distribution and histological studies. Groups of 15 7-dayold BALB/c mice were infected by the i.m. route with 10 4 TCID 50 virus. At the indicated times p.i., three mice from each group were anaesthetized by i.p. injection with a mixture of xylazine (20 mg ml 21 ) and ketamine (100 mg ml 21 ) in PBS at 5 ml (g body weight)
21
. Whole blood was collected by intracardiac puncture and stored at 280 uC. After perfusion with PBS, tissue samples were then collected, weighed individually, snap-frozen in liquid nitrogen and stored at 280 uC. Tissues were homogenized with a Dounce homogenizer and the homogenates prepared as 10 % (w/v) suspensions in Hanks' balanced salt solution (pH 8.0). Virus titres in each tissue homogenate were determined by TCID 50 assay; titres are expressed as TCID 50 (ml whole blood) 21 or (g tissue) 21 (TCID 50 ml 21 or g
).
Tissues for histological analysis were snap-frozen in Tissue-Tek OCT compound (Sakura Finetek USA) in liquid nitrogen. Frozen tissue sections (6 mm) were cut on a microtome and then mounted onto Superfrost glass slides (VWR Labware), fixed in 10 % formalin (pH 8.0) and stained with haematoxylin and eosin.
RESULTS
Mouse-adapted HEV71 has increased virulence in newborn mice
Infection of newborn mice by i.c. inoculation of HEV71-26M does not cause clinically overt disease. In order to create a mouse-adapted strain, HEV71-26M was passaged six times (m.o.i. of 1) in CHO cells to produce a CHO celladapted virus strain (CHO-26M). CHO-26M was then passaged six times by i.c. inoculation of newborn BALB/c mice (10 3 TCID 50 virus in 10 % mouse brain suspensions). By the fourth mouse passage, infection caused 100 % mortality (data not shown). Virus at the sixth mouse passage was cultured twice on Vero cells to generate virus stocks and was designated MP-26M. As both HEV71-26M and CHO-26M are non-virulent in newborn BALB/c mice (Fig. 2) , CHO-26M was selected as the parental strain for comparison with MP-26M in mouse virulence assays.
In order to compare the virulence of MP-26M and CHO-26M, groups of five to ten 1-day-old BALB/c mice were inoculated with 10-fold serial dilutions (10 1 -10 23 TCID 50 ) of CHO-26M or MP-26M by i.c. or i.p. inoculation. MP-26M showed significantly greater virulence in newborn BALB/c mice than CHO-26M (Fig. 2) . Mice infected with CHO-26M did not develop clinical signs of infection at any virus dose. By contrast, all MP-26M-infected mice developed fore-and/or hindlimb paralysis, irrespective of the route of inoculation (data not shown). Mice succumbed to MP-26M infection between 4 and 9 days after i.c. inoculation (Fig. 2a) and between 3 and 8 days after i.p. inoculation (Fig. 2b) 
Susceptibility of BALB/c mice to infection with mouse-adapted HEV71
The age dependence of BALB/c mice to infection with MP-26M after i.c. inoculation was investigated by infecting groups of four to eight mice at 1, 3, 5, 7, 9, 14 and 21 days of age with 10 HD 50 (3.2 TCID 50 ) of MP-26M; the results are shown in Fig. 2(c) . Mice aged between 1 and 3 days had a similar mortality profile, with death commencing at 4 days p.i. and reaching 100 % mortality by 7 days p.i. Mice aged 5-7 days at infection survived until day 5 p.i. and reached mortalities of 83.5 and 80.0 %, respectively, by 8 days p.i. All 9-day-old mice survived to 6 days p.i. and 60.0 % mortality was observed in this age group at 8 days p.i. Mice infected with MP-26M at 14 days of age and older did not develop clinical signs of infection and all survived to 21 days p.i. Seven-day-old mice were selected for all subsequent experiments.
In order to determine whether host susceptibility to MP-26M was dependent on virus dose and route of inoculation, groups of four to eight 7-day-old mice were inoculated with 10-fold serial dilutions of virus by either the i.c., i.p. or i.m. route; the results are shown in MP-26M-infected mice showed similar clinical signs of infection, irrespective of the route and dose of inoculation.
Tissue distribution of CHO-26M and MP-26M in 7-day-old BALB/c mice after i.m. inoculation
In order to investigate differences in tissue tropism between MP-26M and CHO-26M, the distribution of both viruses in host tissues was compared after i.m. inoculation. Groups of 7-day-old BALB/c mice (15 per group) were inoculated by the i.m. route with 1.5610 4 TCID 50 MP-26M or CHO-26M. Whole blood and tissue samples, including heart, liver, spleen, skeletal muscle and brain, were collected at 1, 3, 5 and 7 days p.i. and virus titres determined by TCID 50 assay (Fig. 3) .
CHO-26M was isolated from the site of inoculation at all times p.i., with the virus titre peaking at .10 6 TCID 50 g 21 at 3 days p.i. (Fig. 3a) . CHO-26M was also detected at a single uninoculated skeletal muscle site of three individual mice at 1, 3 and 5 days p. ) and remained high (.10 6 TCID 50 g 21 ) at 5 and 7 days p.i. (Fig. 3b) . Viraemia was first detected at 3 days p.i. and was maintained at similar titres (~10 3 TCID 50 ml
21
) throughout the experiment. Virus first appeared in heart and spleen and in skeletal muscle of the uninoculated limbs at 3 days p.i. and coincided with viraemia, suggesting haematogenous spread (Fig. 3b) . All MP-26M-infected mice developed flaccid limb paralysis by 5 days p.i. Mice that survived to day 7 also developed a hunched posture, listlessness and weight loss. Virus titres in uninoculated and inoculated skeletal muscle groups were almost identical at 5 and 7 days p.i., indicating that skeletal muscle is the primary site of MP-26M replication and the likely source of viraemia. Virus appeared in the central nervous system of all MP-26M-infected mice at 5 days p.i., 48 h after the onset of viraemia (Fig. 3b) .
Histological analysis of HEV71-infected tissues
In order to characterize further the pathogenesis of MP-26M and CHO-26M in 7-day-old mice, histological changes in the tissues of virus-infected mice were examined. The most notable histological changes in CHO-26M-infected mice were identified in skeletal muscle. Neutrophil infiltration was observed in the left (inoculated) hindlimb and in the right forelimb at 5 and 7 days p.i. (Fig. 4) . Mild neutrophil infiltration was also observed in skeletal muscle of both right fore-and hindlimbs at 7 days p.i. No obvious abnormalities were observed in the heart, liver or spleen of CHO-26M-infected mice at any time p.i. However, solitary lymphocytic inflammatory foci were observed in the cervical and lumbar spinal cord sections of two CHO-26M-infected mice at 7 days p.i. (Fig. 4) . By contrast, intense neutrophil infiltration and necrosis of skeletal muscle was observed at the site of inoculation in MP-26M-infected mice at 3 days p.i. By 5 days p.i., marked neutrophil infiltration was observed in all skeletal muscle groups, with necrotizing myositis developing by 7 days p.i. (Fig. 4) . In addition, mild neutrophil infiltration was observed in single thoracic and lumbar spinal cord sections of two mice at 7 days p.i. (Fig. 4) . No obvious histological abnormality was observed in heart, liver or spleen tissue at any time after infection, despite the growth of MP-26M in these tissues (Fig. 3b) .
Nucleotide sequence comparison of the genomes of HEV71-26M, CHO-26M and MP-26M
The complete nucleotide and deduced amino acid sequences of HEV71-26M, CHO-26M and MP-26M were compared in order to identify mutations associated with adaptation of virus to growth in CHO cells and in BALB/c mice (Fig. 5c) . Comparison of the HEV71-26M and CHO-26M sequences revealed four nucleotide differences, all of which were located in the virus polyprotein open reading frame (ORF); only one of these mutations resulted in a 
AI) increases the growth of HEV71 in CHO cells
In order to determine whether the VP2 (K 149 AI) mutation was responsible for the improved growth of virus in cell culture, single-step growth analysis was undertaken in RD and CHO cells using CDV populations of HEV71-26M (CDV-HEV71-26M) and CHO-26M (CDV-CHO-26M).
The single-step growth kinetics and virus yields of both viruses were almost identical in RD cells (Fig. 5a) . By contrast, CDV-CHO-26M replicated more efficiently than CDV-HEV71-26M in CHO cells, with maximum titres more than 100-fold higher than that of parental virus (Fig. 5b) .
A single amino acid substitution in VP1 (G 145 AE) determines the mouse virulence phenotype of HEV71
In order to identify genetic changes associated with the increased virulence observed in mouse-adapted virus (MP-26M), 7-day-old BALB/c mice (eight to 12 per group) were inoculated by the i.m. route with 10 4 TCID 50 of each infectious CDV population ( Table 2) . As expected, the CDV-HEV71-26M and CDV-CHO-26M virus populations caused no observable morbidity or mortality in infected mice. By contrast, CDV-MP-26M caused 100 % mortality ).
Mouse adaptation by enterovirus 71
with a mean (±SEM) survival time of 5.0 (±0.0) days p.i. Interestingly, CDV-CHO-26M-VP1m and CDV-CHO-26M-2Cm had markedly different mouse virulence phenotypes. CDV-CHO-26M-2Cm caused no observable signs of infection and no mortality in 7-day-old mice. By contrast, CDV-CHO-26M-VP1m caused 100 % morbidity and mortality, with a mean survival time of 4.9 (±0.35) days p.i., similar to the parental MP-26M.
HD 50 values for all CDV HEV71 variants were determined by i.m. inoculation of 7-day-old BALB/c mice (eight to ten per group) with serial 10-fold dilutions of virus. Only CDV-MP-26M and CDV-CHO-26M-VP1m produced measurable HD 50 values of 5.0 and 1.6 TCID 50 , respectively (Table 2 ). This result clearly demonstrated that a non-conservative amino acid substitution in VP1 (G 145 AE) alone was sufficient to confer the mouse virulence phenotype observed in both wild-type and clone-derived MP-26M.
The growth of each of the infectious CDV populations was examined in RD cells. CDV-HEV71-26M, CDV-CHO-26M and CDV-CHO-26M-2Cm displayed identical single-step growth kinetics in RD cells, reaching maximum titres of approximately 10 7.5 TCID 50 ml 21 at 12 h p.i. (Fig. 5a ). The two virus strains containing the VP1 (G 145 AE) mutation, CDV-CHO-26M-VP1m and CDV-MP-26M, grew poorly in RD cells compared with the other viruses, with peak titres approximately 100-fold lower than CDV-HEV71-26M, CDV-CHO-26M and CDV-CHO-26M-2Cm at 12 h p.i. (Fig. 5a) . 4 TCID 50 CHO-26M or MP-26M. Three mice were sacrificed on days 1, 3, 5 and 7 p.i. and tissues collected as outlined in Methods. In MP-26M-infected tissues (right column), neutrophil infiltration and necrosis of skeletal muscle (arrows) were seen at 7 days p.i., and infiltrating neutrophils (arrows) were also observed in thoracic and lumbar spinal cord sections of two mice at 7 days p.i. In CHO-26M-infected tissues (middle column), neutrophil infiltration (arrow) was seen in skeletal muscle and in cervical and lumbar spinal cord sections (arrows) of two mice at 7 days p.i. Mock-infected tissues are shown in the left column. Magnification, ¾200.
Stability of the MP-26M-associated VP1 (G 2876 AA) and 2C (A 4727 AG) mutations during passage in 7-day-old BALB/c mice and in RD cell culture Amino acid substitutions introduced during mouse adaptation may revert to that of the parental virus during cell-culture passage (Jia et al., 2001) . To determine whether the amino acid substitutions observed in VP1 and/or 2C of mouse-adapted virus would revert to the wild-type sequence during passage in cell culture, the stability of these mutations was determined by examining the VP1 (G 2876 AA) and 2C (A 4727 AG) nucleotide sequences of CDV-MP-26M at increasing passage levels in RD cells. CDV-MP-26M was cultured at an m.o.i. of 1 for five passages in RD cells and viral RNA was extracted from culture supernatants at approximately 16-18 h p.i. at each passage level. The VP1 and 2C genes were amplified by RT-PCR and their nucleotide sequences determined (Table  3 ). The 2C gene mutation was retained during the five passages in RD cells. By contrast, the VP1 gene mutation had reverted to the wild-type EV71-26M sequence by the second RD cell passage.
As the VP1 (G 2876 AA) mutation rapidly reverted to the wild-type sequence during passage in RD cells, the stability of the mouse-adapted VP1 and 2C mutations was also investigated during passage in mice. CDV-MP-26M was passaged five times in 7-day-old BALB/c mice by i.m. inoculation (10 4 TCID 50 ). Viral genomic RNA recovered from brain and muscle specimens at each passage level was amplified by RT-PCR using primers specific for the VP1 and 2C genes and the amplicons were sequenced (Table 3) . In contrast to RD cell passage, both the VP1 (G 2876 AA) and 2C (A 4727 AG) mutations persisted for five passages in BALB/c mice.
DISCUSSION
Similar to all human enteroviruses, HEV71 has a limited host range, with humans the only known natural host. Although Old World monkeys such as cynomolgus, rhesus and African green monkeys can be infected experimentally with HEV71 (Chumakov et al., 1979; Hashimoto & Hagiwara, 1982; Hashimoto et al., 1978) , other animal species, including rodents, are resistant to infection. In a previous study (Chen et al., 2004) as well as in our study, a mouse-adapted strain of HEV71 was selected by serial passage of virus in mouse brain. However, the molecular mechanism of host-range adaptation by HEV71 has not been clarified.
In order to select a mouse-adapted strain of HEV71, the virus was firstly passaged six times in CHO cells. A non-conservative amino acid substitution in the capsid protein VP2 (K 149 AI) was identified in CHO-adapted virus. Comparison of the single-step growth kinetics of CDV-HEV71-26M and CDV-CHO-26M in CHO cells clearly demonstrated that the VP2 (K 149 AI) mutation was responsible for the improved growth of CDV-CHO-26M in this cell line. Chen et al. (2004) adapted a clinical isolate of HEV71 (MP-4643) to grow in random-bred ICR mice. Mice infected by the i.p. route with the mouse-adapted strain died in an age-and virus dose-dependent manner. Interestingly, the only capsid protein mutation identified in the mouse-adapted virus selected by Chen et al. (2004) was located at the same position in VP2, with the positively charged lysine residue substituted by a non-polar leucine residue . Thus, repeated selection at this site in VP2 during mouse (Chen et al., 2004) or CHO cell (our study) passage suggests that this residue plays an important role in the infection cycle of HEV71 in rodent cells.
The VP2 mutation identified in CHO-26M is located in the EF loop, a major neutralizing antigenic site for the related poliovirus (Burke et al., 1991) . VP2 forms part of a deep cleft on the virion surface of poliovirus that functions as the site of virion attachment to the cellular receptor (Hogle et al., 1985) . In the related poliovirus, amino acid residues in the EF loop and on the inner surface of the N terminus of VP2 have been associated with mouse adaptation (Couderc et al., 1994 (Couderc et al., , 1993 (Couderc et al., , 1996 . However, the VP2 (K 149 AI) mutation identified in CHO-26M was not sufficient to confer the mouse virulent phenotype, but only conferred improved growth in CHO cells. Studies of virus binding and internalization in CHO cells will help to clarify the mechanism by which this mutation confers CHO cell adaptation.
In our study, only viruses expressing the VP1 (G 145 AE) mutation (MP-26M and CHO-26M-VP1m) were virulent in 7-day-old BALB/c mice, indicating that the VP1 (G 145 AE) change is a major genetic determinant of mouse adaptation and virulence. Arita et al. (2008) recently demonstrated an identical mutation responsible for adaptation of HEV71 to growth in SCID/NOD mice. 
*RD cells were infected with CDV MP-26M at an m.o.i. of 1 for five serial passages. RNA was extracted from infected cell-culture supernatants at 18 h p.i., the VP1 and 2C genes were amplified by RT-PCR and the amplicons were sequenced. DGroups of 7-day-old BALB/c mice were infected by the i.m. route (10 4 TCID 50 ) with CDV MP-26M for five serial passages. RNA was extracted from brain and skeletal muscle tissue collected at 5 days p.i., the VP1 and 2C genes were amplified by RT-PCR and the amplicons were sequenced.
This amino acid substitution was located on the surfaceexposed DE loop of VP1. Amino acid mutations in the DE loop of the poliovirus VP1 protein display altered heatinduced and receptor-mediated capsid conformational changes (Colston & Racaniello, 1995; Martin et al., 1988 Martin et al., , 1991 Wien et al., 1997) . Taken together, these data suggest that mouse adaptation by HEV71 may involve an early step in virus replication, in particular a change in the specificity of receptor binding. It is likely that parental HEV71-26M is unable to infect mice due to an inability to bind to or enter mouse cells in order to initiate infection. Alternatively, the VP1 G 145 AE mutation may allow HEV71 to undergo mouse cell-specific post-binding capsid conformational changes or cell penetration. Further investigation is needed to understand the mechanism by which this mutation confers mouse adaptation.
Residue 145 of HEV71 VP1 is highly variable and several residues, including glycine, glutamic acid, arginine and alanine, have been identified in field isolates (Cardosa et al., 2003; McMinn et al., 2001b) . Moreover, we could not isolate a CDV population that included only the G 145 AE mutation due to reversion to the wild-type sequence after a single passage in RD cells. This suggests that the CHOassociated VP2 residue I 149 may help to stabilize VP1 residue E 145 via an as-yet-unknown interaction between these two capsid proteins. Furthermore, the VP2 and VP1 interaction may cooperate to introduce structural change in the virion that either allows the recognition of a mouse cell receptor or may facilitate receptor-mediated conformational changes after attachment.
In addition to the VP1 (G 145 AE) mutation identified in MP-26M, a second amino acid substitution was identified in protein 2C (K 216 AR). This mutation was in a different location to the four amino acid substitutions identified in the protein 2C of the mouse-adapted strain MP-4643 (Chen et al., 2004) . Protein 2C functions as a nucleotide triphosphatase and as a director of viral replication complexes to cell membranes (Pfister & Wimmer, 1999; Teterina et al., 2001) , and may also play a role in virion assembly (Li & Baltimore, 1990; Vance et al., 1997) . In our study, the 2C (K 216 AR) mutation was not responsible for the mouse virulence phenotype. Furthermore, no differences in either cell-culture growth characteristics or plaque morphology were identified between viruses expressing the wild-type (lysine) or mutant (arginine) residue at position 216 in 2C (data not shown). Thus, the significance of the protein 2C mutation in mouse adaptation remains unclear.
We have shown that skeletal muscle is the primary site of HEV71 replication in mice. As expected, mouse-adapted virus grew more efficiently in skeletal muscle than parental virus, yielding approximately 10-fold higher titres. Histological analysis of skeletal muscle showed that infection with CHO-26M induced only mild neutrophil infiltration, whereas infection with mouse-adapted virus induced marked neutrophil infiltration and severe necrotizing myositis. The presence of necrotizing myositis in MP-26M-infected mice and a lack of evidence of central nervous system disease suggests that the flaccid paralysis observed was due primarily to myositis.
In conclusion, we characterized the molecular basis of CHO cell and mouse adaptation by HEV71. An amino acid change in VP2 (K 149 AI) was solely responsible for adaptation of virus to growth in CHO cells. Moreover, an amino acid change in VP1 (G 145 AE) was solely responsible for mouse adaptation and increased virulence in BALB/c mice. The CHO cell and mouse adaptation determinants are likely to be involved in an early event in virus replication, such as virus binding and penetration of the cell surface. The identification of viral genomic regions responsible for the expanded host range and increased virulence in mice has significantly enhanced our understanding of the molecular biology of HEV71. Furthermore, knowledge gained from this study will assist in furthering research on virulence of this increasingly important human pathogen.
